Drug intelligence / Profile preview

UCB8600

Development stage: Discontinued
Lead developer: UCB
Modality: Small Molecules
Administration: Oral

Overview

UCB8600 is an investigational small molecule drug developed by UCB for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis. It was designed as an oral therapy and reached Phase 1 clinical trials, where it was evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants as well as those with atopic conditions and CSU. The precise mechanism of action has not been publicly disclosed. Development was discontinued after the termination of its initial clinical study[1][2][3][5].

Beyond the preview

Go deeper on UCB8600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UCB8600.

Explore the full profile